Christopher Viehbacher
CIK: 0001774478
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (12 total)
- Aug 7, 2026BRVE
Braveheart Bio, Inc.
Purchase(P)Direct83.3K shares at avg. $18.00$1.5M - Aug 5, 2026BRVE
Braveheart Bio, Inc.
Award(A)DirectStock Option (Right to Buy)
30K shares- - Feb 13, 2026BIIB
BIOGEN INC.
Award(A)DirectRestricted Stock Unit
38K shares- - Feb 6, 2026BIIB
BIOGEN INC.
Exercise(M)Direct15.5K shares- - Feb 6, 2026BIIB
BIOGEN INC.
Exercise(M)Direct9K shares- - Feb 6, 2026BIIB
BIOGEN INC.
Tax Payment(F)Direct4.4K shares at avg. $201.18$876K - Feb 6, 2026BIIB
BIOGEN INC.
Tax Payment(F)Direct6.6K shares at avg. $201.18$1.3M - Dec 1, 2025BIIB
BIOGEN INC.
Tax Payment(F)Direct3.4K shares at avg. $177.78$605K - Dec 1, 2025BIIB
BIOGEN INC.
Exercise(M)Direct7K shares- - Feb 7, 2025BIIB
BIOGEN INC.
Tax Payment(F)Direct3.2K shares at avg. $141.35$452K - Feb 7, 2025BIIB
BIOGEN INC.
Exercise(M)Direct9K shares- - Feb 6, 2025BIIB
BIOGEN INC.
Award(A)DirectRestricted Stock Unit
46.4K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Aug 7, 2026 |  BRVE Braveheart Bio, Inc. | Purchase(P) | 83,333 | $18.00 | $1,499,994 | Direct |
| Aug 5, 2026 | BRVE Braveheart Bio, Inc. | Award(A) Stock Option (Right to Buy) | 30,000 | - | - | Direct |
| Feb 13, 2026 |  BIIB BIOGEN INC. | Award(A) Restricted Stock Unit | 38,015 | - | - | Direct |
| Feb 6, 2026 | BIIB BIOGEN INC. | Exercise(M) | 15,453 | - | $0 | Direct |
| Feb 6, 2026 | BIIB BIOGEN INC. | Exercise(M) | 9,008 | - | $0 | Direct |
| Feb 6, 2026 | BIIB BIOGEN INC. | Tax Payment(F) | 4,356 | $201.18 | $876,340 | Direct |
| Feb 6, 2026 | BIIB BIOGEN INC. | Tax Payment(F) | 6,624 | $201.18 | $1,332,616 | Direct |
| Dec 1, 2025 | BIIB BIOGEN INC. | Tax Payment(F) | 3,404 | $177.78 | $605,163 | Direct |
| Dec 1, 2025 | BIIB BIOGEN INC. | Exercise(M) | 7,040 | - | - | Direct |
| Feb 7, 2025 | BIIB BIOGEN INC. | Tax Payment(F) | 3,201 | $141.35 | $452,461 | Direct |
| Feb 7, 2025 | BIIB BIOGEN INC. | Exercise(M) | 9,008 | - | - | Direct |
| Feb 6, 2025 | BIIB BIOGEN INC. | Award(A) Restricted Stock Unit | 46,360 | - | - | Direct |
1-12 of 12 transactions
About Viehbacher Christopher
Viehbacher Christopher (SEC CIK 0001774478) files insider reports with the SEC as Director of Braveheart Bio, Inc. (BRVE) and President and CEO of BIOGEN INC. (BIIB).
Signal8 holds 6 ownership filings by Viehbacher Christopher (1 Form 3, 5 Form 4), filed between Feb 10, 2025 and Aug 7, 2026. Those filings report 12 transactions, from Feb 6, 2025 to Aug 7, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Viehbacher Christopher's filings is in SAN FRANCISCO, CA.
Recent filings by Viehbacher Christopher
- Aug 7, 2026: Open-market purchase of BRVE shares (Form 4, code P).
- Aug 5, 2026: Grant or award of BRVE derivative securities (Form 4, code A).
- Feb 13, 2026: Grant or award of BIIB derivative securities (Form 4, code A).
- Feb 6, 2026: Option exercises of BIIB shares (2 lines, Form 4, code M).
- Feb 6, 2026: Tax withholdings of BIIB shares (2 lines, Form 4, code F).
Other insiders filing for Braveheart Bio, Inc. (BRVE)
- Agarwala Vineeta, Director
- AH Bio Fund IV, L.P., 10% Owner
- Chimovits Erez, Director
- ORBIMED ADVISORS LLC, Director
- Jiangsu Hengrui Pharmaceuticals Co., Ltd., 10% Owner
- Forbion Growth Opportunities Fund III Cooperatief U.A., 10% Owner